Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2013

Das C, Tyler JK. Histone exchange and histone modifications during transcription and aging. Biochim Biophys Acta. 2013;1819(3-4):332-342.

Brady N, Chuntova P, Bade LK, Schwertfeger KL. The FGF/FGFR axis as a therapeutic target in breast cancer. Expert Rev Endocrinol Metab. 2013;8(4):391-402.

Chaser BE, Renszel KM, A Crowson N, Osmundson A, Shendrik IV, Yob EH, et al. Onycholemmal carcinoma: a morphologic comparison of 6 reported cases. J Am Acad Dermatol. 2013;68(2):290-5.

Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, et al. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol. 2013;26(6):835-48.

Zinn RL, Gardner EE, Dobromilskaya I, Murphy S, Marchionni L, Hann CL, et al. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Mol Cancer. 2013;12:16.

Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood. 2013;122(12):2083-92.

Shendrik I, Crowson AN, Magro CM. Follicular cutaneous squamous cell carcinoma: an under-recognized neoplasm arising from hair appendage structures. Br J Dermatol. 2013;169(2):384-8.

Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, et al. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Front Oncol. 2013;3:214.

Mitsiades CS, Chen-Kiang S. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol. 2013;88 Suppl 1:S5-13.

Xiong MY, Rizzo AE, Cohen TS, Dyer RK, Korgavkar K, Bingham SF, et al. Predictors of squamous cell carcinoma in high-risk patients in the VATTC trial. J Invest Dermatol. 2013;133(6):1521-32.